Real-World Study Links Acoramidis to Better Outcomes Than Tafamidis in ATTR-CM
BridgeBio Pharma reported independent real-world data associating acoramidis with an 18% lower risk of a composite clinical outcome than tafamidis in ATTR-CM. The matched electronic health record analysis included 2,684 patients and found lower hospitalization risks, though mortality and new-onset atrial fibrillation differences were not statistically significant. The company noted possible residual confounding, relatively short follow-up, and that full results are still under peer review.
BridgeBio Pharma said an independent analysis of U.S. electronic health records linked acoramidis with an 18% lower risk on a combined clinical measure than tafamidis in ATTR-CM. The matched study covered 2,684 patients. The combined measure included death, any hospital admission, newly detected atrial fibrillation, and greater diuretic need.
Hospitalization results favored acoramidis: cardiovascular admissions fell 27%, heart-failure admissions fell 27%, and all-cause admissions fell 25%. Differences in death and new-onset atrial fibrillation were not statistically significant. The company noted possible remaining confounding, limited follow-up duration, and that the full findings have not completed peer review.
If confirmed, these findings could shape treatment conversations for people with ATTR-CM and their clinicians, potentially reducing hospital stays and easing burdens on patients, caregivers, and health systems. Payers may consider the data when making coverage or formulary choices. Because the analysis is real-world, not randomized, and still under peer review, any societal benefit remains uncertain; mortality and atrial fibrillation questions may leave patients and doctors weighing trade-offs carefully.